Author:
H. Shiu Justin,N. Pham Heather,Singh Navneet,J. Sweidan Alexander
Abstract
Statins are a well-established class of β-Hydroxy β-methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors that have recently been discussed as a possible therapeutic in COVID-19. The breadth of this chapter reviews the evidence for use of statins alone or in combination with other drugs as treatment for patients hospitalized with moderate to severe COVID-19. Discussion will include a (1) biochemical argument for the role of statins in COVID-19, (2) a systematic literature review of relevant studies to date, and (3) an investigation into early-phase interventional studies. Outcome measures based on all aforementioned relevant studies will be clearly defined and compared.
Reference70 articles.
1. WHO COVID-19 Dashboard. Geneva: World Health Organization. 2020. Available from: [last cited: 1/23/23]
2. Research C for DE and Coronavirus (COVID-19) — Drugs. FDA. Published December 22. 2022. [Accessed January 24, 2023]. Available from:
3. Therapies. COVID-19 treatment guidelines. [Accessed January 24, 2023]. Available from:
4. Therapeutics and COVID-19: living guideline. [Accessed January 24, 2023]. Available from:
5. Chen F, Hao L, Zhu S, et al. Potential adverse effects of dexamethasone therapy on COVID-19 patients: Review and recommendations. Infectious Disease and Therapy. 2021;(4):1907-1931. DOI: 10.1007/s40121-021-00500-z